Onkos Surgical Announces Market Leading Growth and Strategy at Premier MedTech Investor Conferences

Company shares strategy for robust growth

PARSIPPANY, N.J., March 23, 2022 /PRNewswire/ -- Onkos Surgical, a leading innovator of solutions for musculoskeletal oncology and complex orthopaedic procedures, presented its plans for accelerated commercial growth and further expansion of its product offerings at two premier MedTech investor meetings that precede the 2022 American Academy of Orthopedic Surgeons annual meeting. Accelerating through the pandemic, Onkos posted 22% growth in 2020 and 29% growth in 2021 outpacing the orthopaedic market as a whole.

Onkos Surgical Co-Founder and CEO Patrick Treacy shared these updates at the 2022 Life Science Intelligence Emerging MedTech Summit and the 2022 Canaccord Genuity Musculoskeletal Conference. The Company previously announced on September 1, 2021 that it had closed its Series C funding round, which has accelerated Onkos' commercial presence, innovation pipeline and manufacturing footprint.

Treacy commented, "While much of the industry is focused on the race toward outpatient surgery and robots, Onkos Surgical is well positioned to bring differentiated innovation to musculoskeletal oncology and other complex orthopaedic conditions. Our portfolio strategy is focused on expanding innovation in the areas of limb reconstruction, metastatic disease, advanced-stage revision and deformity, all underscored by novel patient specific approaches. In the last year alone, we have launched two, first of their kind 3D printed limb reconstruction implants while loading the new product pipeline with game changing innovation.

"Onkos is developing some of the only products and services focused on surgeons like myself, who are treating cancer and other complex musculoskeletal conditions. Their recent innovations leveraging 3D printing have made a difference in how I treat my patients" said Dr. Steven Gitelis, Onkos Surgical Chief Medical Officer, Rush Medical College Endowed Professor and Chief of the Musculoskeletal Oncology Program at Rush Cancer Center. "Their dedication and focus on the treatment of infection, metastatic disease, and advanced reconstructive solutions is essential to improving patient care."  

Onkos Surgical is exhibiting at this week's American Academy of Orthopaedic Surgeons Conference in Chicago, IL and can be found at booth #636 in the McCormick Center Exhibitor Hall. 

For more information on Onkos Surgical and its products and services, please visit www.onkossurgical.com. 

About Onkos Surgical
Onkos Surgical is a leader in innovative solutions for musculoskeletal oncology and complex orthopaedic procedures. With our Precision Orthopaedics approach, surgeons are better informed about patient-specific clinical challenges and are able to plan and implement a more precise reconstruction. Our personalized approach supports improved patient outcomes and experiences using the latest innovations in virtual surgical planning, 3D modeling and printing, implant design, and workflow optimization. More than 350 of the leading academic medical institutions in the US choose Onkos Surgical Precision Orthopaedics.

Forward Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "future," "believes," "expects," "may," "will," "should," "potential," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management's beliefs, assumptions and current expectations but are subject to known and unknown risks and uncertainties including, without limitation, market trends and demand, supply chain interruptions and other potential effects of the continuing COVID-19 pandemic. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results. The forward-looking statements included are made only as the date of this release. The company assumes no obligation to update any information or forward-looking statement contained herein, save for any information required to be disclosed by law. 

Media Contacts:
Sean Curry
SVP, Commercial Operations
Onkos Surgical
[email protected]
973.264.5400

SOURCE Onkos Surgical

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED